A nasal vaccine that could finally curb Covid infections is one step closer to a reality after promising early trial results. The inhaled vaccine, made by researchers in Georgia, successfully reduced the risk of symptomatic Covid infections by 86 percent for three months in people who received it as a booster - almost double the protection the mRNA boosters provide. While still in early stages, it is an exciting development that could prove more effective than the booster doses administered as injections. The nasal, or ‘mucosal’ vaccines are appealing for their ability to prime immune cells in the mucous membranes...
